With a partial government shutdown underway, House Speaker Mike Johnson confronts a dual crisis: securing passage of a federal funding package and mediating an intensifying political battle over the scope and tactics of Immigration and Customs Enforcement operations.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Blockchain security firm CertiK reports a dramatic spike in cryptocurrency thefts for January 2026, with losses hitting $370.3 million—the highest monthly figure in 11 months. The surge is driven by a mix of sophisticated social engineering attacks and persistent on-chain exploits, highlighting the evolving threats facing the digital asset space.
The business intelligence firm, the world's largest corporate holder of Bitcoin, is now sitting on nearly $1 billion in paper losses after the cryptocurrency's recent slump below its average acquisition cost, raising questions about its high-stakes treasury strategy.
Israel is set to partially reopen the Rafah border crossing with Egypt, allowing limited pedestrian movement for Palestinians. The move, a condition of the U.S.-brokered ceasefire, comes amid ongoing tensions and a continued ban on foreign journalists.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Palantir Technologies expands its strategic footprint in Asia through a deepened partnership with HD Hyundai, while securing a pivotal role in building sovereign AI data centers across Europe, the Middle East, and Africa with Sovereign AI and Accenture.
Certified financial planner and popular financial educator Kevin Lum outlines a crucial mindset shift for those nearing or in retirement, urging them to move beyond accumulation and toward purposeful living.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
As gold and silver surged to record highs last month, Bitcoin's puzzling stagnation below $90,000 had traders searching for answers. A closer look at exchange order books reveals a deliberate play by large players to suppress price—a tactic that ultimately set the stage for last week's sharp decline.
Bitcoin experienced a sharp, V-shaped recovery after briefly tumbling near $74,000, a swing exacerbated by critically thin market liquidity. The move liquidated over half a billion dollars in leveraged positions, underscoring heightened volatility as traders navigate a market lacking depth.
Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Two of the largest known Ethereum holders, BitcoinOG and Trend Research, have strategically sold a combined $371 million worth of ETH to repay loans on the Aave protocol. This voluntary deleveraging, distinct from over $140 million in automated liquidations processed by Aave, highlights a shift towards caution among major crypto players amid market volatility.
As Europe's markets navigate a fragile recovery, investors are turning to dividend-paying stocks for income and resilience. We examine three companies offering attractive yields, weighing their potential against underlying financial risks.
Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
Fresenius SE & Co. KGaA (ETR:FRE) faces a challenging period as its stock declines, with a key profitability metric and a high dividend payout strategy raising questions about its near-term growth prospects.
